← All trials
NCT04931459
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jun 18, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 62
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Acumen PharmaceuticalsLead sponsor
- National Institute on Aging (NIA)Collaborator
- Acumen PharmaceuticalsOverall official - principal investigator
- Acumen PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.